focus -WSS

focus

author：knowledge 2025-09-27 13:03:34 - browse：835

Judge's gavel — Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： U.K. researchers warn about biases in medical devices, algorithms

hotspot

focus

WSS

Eli Lilly to pay $200M for Beam’s stake in gene

Hospitals warn Medicare's drug payment fix is ‘unlawful’

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Readout Newsletter: Bluebird, CVS, Contineum

App could help diagnose ear infections more accurately — and at home

Colonoscopy prep: Liquid

knowledge

focus

focus

Apple is now the first public company to be valued at $3 trillion

Biden's order seeks to regulate AI risk without stifling innovation

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Physician subsidies by hospitals soar in wake of No Surprises Act

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout Newsletter: New research from Sanofi, Regeneron, etc.

ChatGPT in medicine: STAT answers readers' burning questions

Creating egg and sperm cells from stem cells raises ethical issues

Drug repurposing or repositioning? The language matters

Paying for Covid pills will soon shift to insurers

hotspot

U.K. researchers warn about biases in medical devices, algorithms

Readout Newsletter: XBI biotech index, Akero Therapeutics

Baby aspirin cuts fat buildup in liver disease patients, in small study

Biden's order seeks to regulate AI risk without stifling innovation

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Eli Lilly to pay $200M for Beam’s stake in gene

hotspot

focus

entertainment

leisure time